In addition, our results also suggest that in regard to HbA1c-lowering efficacy, a low-dose of glimepiride is similarly effective as sitagliptin without weight gain or severe hypoglycemia at the early stage of T2DM with low insulin secretion (Table 2 and Additional file 2: Figure S2). The gene discussed is INS; the disease is Hypoglycemia.